A third Phase 2 study of VX-150 is currently ongoing in neuropathic pain with data expected in early 2019. Vertex also recently initiated a Phase 1 study of a second NaV1.8 inhibitor, VX-128 ...

The most common adverse event (≥10% in any treatment group) was headache, which occurred in 24 percent of patients in the VX-150 group and 12 percent of patients in the placebo group.